15 Jul 2016 --- Biotechnology company Gnosis plans to focus on depression with their two products: folate derivative Quatrefolic – the patented glucosamine salt of the (6S)-5-MTHF, and Adomet – the commercially stable form of SAMe for nutraceutical applications.
